TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04503317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active acupuncture low level laser in addition to nasal laser irradiation
Description: laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. applied on specific acupuncture points ( acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time with treadmill aerobic exercise, once per day, 3 times per week for three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill exercise
Description: aerobic exercise once per day, 3 times per week for three months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill exercise
Description: aerobic exercise once per day, 3 times per week for three months
Study: NCT02256696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: 600 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 25mg/kg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 25mg/kg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: 25mg/kg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: 15mg/kg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 300 mg QD
Study: NCT01320397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 6 microgram capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 50 micrograms capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 500 micrograms capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 50 mg once a day
Study: NCT01285843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Minimally Invasive Approach (AMIS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Minimally Invasive Approach (AMIS)
Study: NCT00766766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Risk and Behavioral Skills Coaching Sessions
Description: Health Risk and Behavioral Skills Coaching Sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching Sessions
Description: Telephone Coaching Sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Feedback Letter
Description: Physician Feedback Letter
Study: NCT02114021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone gel
Description: betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine jelly
Description: the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: distilled water
Description: The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: distilled water
Description: The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
Study: NCT03780582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-human interaction
Description: Exploring what kinds of AI-human interaction improve radiologists detection accuracy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-human interaction
Description: Exploring what kinds of AI-human interaction improve radiologists detection accuracy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-human interaction
Description: Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
Study: NCT04335435

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Bran Consumption
Description: Oat bran (120 g), single dose.
Study: NCT04781712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular mHealth for Tailored Rehabilitation
Description: an individually tailored self-management through the mHealth app with a smart band worn on the wrist
Study: NCT02233530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CST intervention
Description: The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
Study: NCT04119687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FX201
Description: FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FX201
Description: FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FX201
Description: FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
Study: NCT02142816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Fluid therapy guided by doppler

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVI'
Description: Fluid therapy guided by PVI
Study: NCT00972270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella LP 2.5
Description: Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Aortic Balloon Pump
Description: The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
Study: NCT05252637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Fascial Posterior Vagina Duplication
Description: Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
Study: NCT02202304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/Thymol varnish
Description: This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine/Thymol varnish
Description: This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
Study: NCT03980067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
Study: NCT03466632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
Study: NCT00490035

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
Study: NCT01108939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimalarial treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Study: NCT04870996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
Study: NCT02283879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
Study: NCT03804281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group
Description: The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
Study: NCT04261140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQUIA Forte Fil
Description: Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clearfil Majesty Esthetic
Description: Apply in 2-mm increment, light cure for 20 s

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NexComp Flow
Description: Apply in 2-mm increment light cure for 20 s

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3M Espe Bulk-fill
Description: Apply in single increment up to 4 mm; light curing for 20 s
Study: NCT04059718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI Thrive Peer-Led Online Self-Management Program
Description: 6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
Study: NCT01724827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ceramic (Empress CAD, Ivoclar Vivadent)
Description: Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: composite (Lava Ultimate, 3M Espe)
Description: Nanohybrid composite resin (Lava Ultimate, 3M Espe)
Study: NCT00743756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: home-delivered meals
Description: 3 diabetic meals per day, 7 days per week for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: home-delivered meals
Description: diabetic meals 3 times per day, 7 days a week for six months

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: diabetes education for 12 months
Description: subjects in this group received diabetes education for 12 months
Study: NCT01447888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150% Oral Morphine Equivalent (OME)
Description: Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Judgment
Description: This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
Study: NCT02414698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Hydrodiscectomy
Description: The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TESI
Description: Transforaminal epidural steroid injections given in the lumbar spine.
Study: NCT01449565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 3 monthly intramuscular injections of naltrexone 380 mg (extended release)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
Study: NCT02783898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor Heart Monitor
Description: Smart phone based ECG event recorder
Study: NCT02391337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Drug intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Drug intervention
Study: NCT00435617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Mentor
Description: Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
Study: NCT00465517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Oral suspension 200-500 mg 3x/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active placebo
Study: NCT01657396

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Hygiene
Description: Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAGE Q-care q2
Description: Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAGE Q-care q2 with Chlorhexidine
Description: Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
Study: NCT02309021

Intervention type: OTHER
Group type: OTHER
Intervention: Sport

Intervention type: OTHER
Group type: OTHER
Intervention: Non-sport activities
Study: NCT02631395

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
Study: NCT01382550

Intervention type: DRUG
Intervention: long-lasting OAT or 12-month OAT
Description: The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (\>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded.
Study: NCT02938780

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo text message
Description: The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition physical activity text message
Description: The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
Study: NCT01563523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC